Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

sful transfer of manufacturing activities to Wyeth during 2007. This decrease was partially offset by increased clinical costs related to the company's Phase IIb clinical trial for TRU-015 and increased personnel-related expenses due to increased headcount.

The 12-month increase was primarily due to increased clinical costs related to the company's Phase IIb clinical trial for TRU-015, increased personnel-related expenses due to increased headcount, and increased outside manufacturing costs related to Trubion's TRU-016 product candidate. These increases were partially offset by lower outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007 and lower non-cash stock-based compensation charges.

Net loss for the fourth quarter of 2007 was $4.9 million, or $0.28 per diluted common share, compared with a net loss of $4.8 million, or $0.33 per diluted common share, for the fourth quarter of 2006. For the year ended Dec. 31, 2007, net loss was $23.3 million, or $1.32 per diluted common share, compared with a net loss of $3.9 million, or $0.83 per diluted common share, for the year ended Dec. 31, 2006.

Trubion had $78.5 million in cash, cash equivalents and investments as of Dec. 31, 2007, compared with $105.8 million as of Dec. 31, 2006.

"In 2007 we continued our mission to develop a family of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience, that could offer improved patient experiences," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "We and our partner continued to advance the clinical development of our lead product candidate, TRU-015, for the treatment of rheumatoid arthritis, began clinical evaluation of TRU-015 in non-Hodgkin's lymphoma (NHL) and expect to do the same in systemic lupus erythematosus (SLE) later this year. In 2008, we expect our research and clinical advance
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s Flametec ... competitive in the semiconductor, clean room and medical ... product quality and productivity, according to Dwight Leatherwood, ... 1980 in Lewisville, TX, Leatherwood Plastics ... the business. Much of Leatherwood’s equipment building relies ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... pirfenidone role in treatment of patients with IPF -- Ground-breaking ... Strong data from 14-day triple combination study of ITMN-191 in ... (Nasdaq: ITMN ) today announced results from operations ... InterMune reported a net loss for the first quarter ...
... ERES ), a leading provider of centralized ECG, ... device, and related industries, announced today results for the first ... refer to changes from the same period a year ago.Highlights ... , Quarterly ...
... 30 Resonant Medical, an innovator in 3D ... appointment of Stephen Whisenhunt to the position of ... will lead the Company,s growing global sales team ... than 18 years of radiation oncology industry experience ...
Cached Biology Technology:InterMune Reports First Quarter 2009 Financial Results and Business Highlights 2InterMune Reports First Quarter 2009 Financial Results and Business Highlights 3InterMune Reports First Quarter 2009 Financial Results and Business Highlights 4InterMune Reports First Quarter 2009 Financial Results and Business Highlights 5InterMune Reports First Quarter 2009 Financial Results and Business Highlights 6InterMune Reports First Quarter 2009 Financial Results and Business Highlights 7InterMune Reports First Quarter 2009 Financial Results and Business Highlights 8InterMune Reports First Quarter 2009 Financial Results and Business Highlights 9InterMune Reports First Quarter 2009 Financial Results and Business Highlights 10InterMune Reports First Quarter 2009 Financial Results and Business Highlights 11InterMune Reports First Quarter 2009 Financial Results and Business Highlights 12InterMune Reports First Quarter 2009 Financial Results and Business Highlights 13ERT Reports First Quarter 2009 Results 2ERT Reports First Quarter 2009 Results 3ERT Reports First Quarter 2009 Results 4ERT Reports First Quarter 2009 Results 5ERT Reports First Quarter 2009 Results 6ERT Reports First Quarter 2009 Results 7ERT Reports First Quarter 2009 Results 8ERT Reports First Quarter 2009 Results 9Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing 2
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... and Duke University have developed nanoscale "patches" that can ... more responsive to signals that control cell activity. The ... engineering research. The research takes advantage of the ... via physical contact. Specifically, when targeted receptors on the ...
... mainland - are taking the lead in making plans to ... Diana Reckien, of Columbia University in the US, in a ... analysed the relevant strategic policies and planning documents of 200 ... in every three European cities has no plans on the ...
... "smart": too elementary to be able to reproduce by themselves, ... of their own DNA so that it is transcribed by ... inject their own genetic material into the cells they infect. ... (the International School for Advanced Studies in Trieste), has studied ...
Cached Biology News:Researchers use nanoscale 'patches' to sensitize targeted cell receptors 2The reality behind Europe's response to climate change 2Tidy knots are faster 2
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
...
Biology Products: